Actinium Pharmaceuticals, Inc.
ATNM
$1.25
$0.021.29%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.57% | -80.96% | -21.42% | -45.74% | -26.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.91% | -64.52% | -14.54% | -54.11% | -39.58% |
| Operating Income | 467.39% | 64.52% | 14.54% | 54.83% | 39.58% |
| Income Before Tax | 505.66% | 65.35% | 10.70% | 55.64% | 39.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 505.66% | 65.35% | 10.70% | 55.64% | 39.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 505.66% | 65.35% | 10.70% | 55.64% | 39.42% |
| EBIT | 467.39% | 64.52% | 14.54% | 54.83% | 39.58% |
| EBITDA | 492.06% | 64.60% | 14.56% | 55.75% | 41.61% |
| EPS Basic | 502.99% | 65.39% | 10.69% | 55.82% | 41.53% |
| Normalized Basic EPS | 503.05% | 65.39% | 10.66% | 55.82% | 41.54% |
| EPS Diluted | 502.99% | 65.39% | 10.69% | 55.82% | 41.53% |
| Normalized Diluted EPS | 502.90% | 65.39% | 10.66% | 55.82% | 41.54% |
| Average Basic Shares Outstanding | 0.65% | 0.13% | -0.03% | 0.40% | 3.63% |
| Average Diluted Shares Outstanding | 0.68% | 0.13% | -0.03% | 0.40% | 3.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |